This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Hang on a second…

This CME Activity has expired and is no longer available for credit.

Evaluating Newer Targeted Therapies for Patients with Rheumatoid Arthritis: Addressing Unmet Needs in the Primary Care Practice

Evaluating Newer Targeted Therapies for Patients with Rheumatoid Arthritis: Addressing Unmet Needs in the Primary Care Practice


Interactive Monograph

Time to Complete

45 minutes


October 6, 2017


October 6, 2018
Add to Queue

Maximum Credits

0.75 / AMA PRA Category 1 CreditTM

Accredited Provider

Provided by Integrity Continuing Education, Inc.

Commercial Supporter

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Program Description

Rheumatoid arthritis (RA) is a chronic, painful, debilitating inflammatory joint disease that affects 1.5 million people in the United States and impacts activities of daily living in many patients. If left untreated, or upon lack of response to treatment, RA is associated with disability, loss of productivity, lowered quality of life, and premature death. RA is also associated with several comorbid conditions such as cardiovascular disease, infection, mental health conditions, and malignancies. Increased hospitalizations and ambulatory visits are also attributed to RA, and patients with RA report significantly poorer quality of life. This disease imposes a significant healthcare burden both on the patient and the healthcare system.

Intended Audience

This educational initiative has been designed for primary care physicians and rheumatologists involved in the management of patients with RA.

Educational Objectives

Upon completion of this educational activity, participants should be able to:

  • Implement routine screening in practice to improve the early and accurate diagnosis of RA
  • Apply guideline recommendations for treating to remission and preserving patient function in RA
  • Review the underlying pathophysiology of RA and the role of emerging targeted therapies, including cytokine inhibition, for patients with RA
  • Implement strategies that promote early identification of important comorbidities and their management in patients with RA

Conflict Of Interest Disclosure Policy

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent COI they may have as related to the content of this activity. All identified COI are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported their financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:


Diane Horowitz, MD
Assistant Professor of Medicine
Division of Rheumatology
Hofstra Northwell School of Medicine
Great Neck, New York
Director, The Rheumatoid Arthritis Center
Director, Rheumatology Continuing Education

Dr. Horowitz discloses the following:
Contracted Research: AbbVie, Amgen, Pfizer

Accredited Provider Disclosure

Patima Tanapat, PhD, has no real or apparent conflicts of interest to disclose.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.

Designation Statement

Integrity Continuing Education designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education, Inc., and Sanofi Genzyme and Regeneron Pharmaceuticals. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.


There are no fees for participating and receiving CME credit for this activity. During the period of October 6, 2017 through October 6, 2018, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pre-test
  • Study the educational activity
  • Complete the post-test and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or better.

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or

If you have any questions relating to your certificate or other issues with this activity, please contact

Privacy Policy


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue